
    
      This is an open-label non-randomized pharmacokinetic (PK) study of Homoharringtonine
      (Omacetaxine Mepesuccinate) administered as a subcutaneous (SC)injection to patients with
      relapsed and/or refractory hematologic malignancies and to patients with advanced solid
      tumors with no bone marrow involvement.
    
  